Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relizorb is a single-use digestive enzyme cartridge designed to hydrolyze (break down) fats in enteral tube-feeding formulas before they enter the body. The device contains iLipase, an immobilized form of the enzyme lipase attached to small beads within the cartridge. As tube-feeding formula passes through Relizorb, the lipase breaks down triglycerides into absorbable fatty acids and monoglycerides, improving fat absorption for patients with fat malabsorption who require enteral nutrition. This process helps increase uptake of essential long-chain polyunsaturated fatty acids such as omega-3s (DHA and EPA), which are important for energy, growth, and development. Relizorb is indicated for pediatric patients aged 1 year and above as well as adults[1][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relizorb.